Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes
Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval...



